XXXX , @entity900 and @entity1487 in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative group.

@entity1 @entity137 @entity6023 @entity417 @entity882 @entity294 @entity900 @entity1311 @entity33 @entity1398 @entity1487
The aim of this multicenter trial was to test the feasibility and the activity of a three-drug combination where @entity1311 is added to @entity900 and @entity1487 . @entity1 with metastatic or relapsed SCC-HN unsuitable for further loco-regional radical treatment, not previously treated with chemotherapy, were eligible to receive @entity1311 160 mg/m2 (3-hr infusion) day 1, CDDP 25 mg/m2/day and @entity1487 250 mg/m2/day bolus on days 1, 2, 3 every three weeks up to a maximum of five courses. Fourty-seven @entity1 were enrolled by five Institutions in Italy. Main grade III-IV @entity137 were: @entity1398 (48%), @entity882 (6%), @entity417 (4%), @entity294 (2%), @entity33 (2%). Six @entity1 had a complete response (13.3%) and eight a partial response (17.8%). Median progression free survival and overall survival are 4.1 and 7.9 months. One-year progression free survival and overall survival are 16% and 29%. This three-drug regimen has an excellent safety profile. The activity in the palliation of recurrent SCC-HN, however, does not appear to be improved in comparison with @entity900 and @entity1487 or @entity900 and @entity1311 regimens. Recent studies indicate a more promising role of @entity6023 including triplets in the induction therapy of previously untreated @entity1 .
